Abstract. The effect of feline infectious peritonitis virus (FIPV) on platelet aggregation and I4C-serotonin release induced by threshold levels of four agonists (adenosine diphosphate [ADP], collagen, arachidonic acid, and epinephrine) was examined in vitro in ten specific-pathogen-free cats. Purified suspensions of FIPV added to stirred platelet suspensions (virus to platelet ratio equal to 1 : 320) 1 minute prior to the addition of agonist potentiated the ADP-induced aggregation response by greater than 100% in seven cats. Platelet 14C-serotonin release was increased by greater than 100% in four cats. Collagen-induced platelet aggregation was enhanced in ten cats while collagen-induced 14C-~er~tonin release was enhanced in eight cats. Potentiation of arachidonic acid-induced platelet aggregation was observed in three cats, two of which demonstrated enhanced platelet I4C-serotonin release. Although epinephrine-induced platelet aggregation was enhanced in five cats, the samples displayed only fine microaggregates. Enhanced 14C-~er~tonin release from platelets in response to epinephrine was not demonstrated. Interaction with the outer platelet membrane and internalization of viral particles within the surface-connected open canalicular system were demonstrated by electron microscopy within 5 minutes of the addition of virus to platelet suspensions with or without added agonists. Decreasing the virus concentration by ten-or one hundred-fold abolished the potentiating effect observed previously, while increasing the concentration tenfold resulted in direct platelet activation in the absence of agonist. Although the specific mechanism of FIPV-induced platelet responses in vitro was not established, the ability of virus to directly activate platelets and the rapid potentiation of responses observed at lower virus concentrations suggested that virus-mediated ion fluxes across platelet membranes were involved.
Immune-mediated thrombocytopenia associated either with viral infection or after immunization with modified live viruses has been documented.lLJ2 In antigen-sensitized individuals, thrombocytopenia occurred as early as 3 to 4 days after viral challenge.
Virus-associated thrombocytopenia may have involved platelet Fc receptors and immune comp l e x e~.~J~ A direct effect of viruses on platelets, however, has also been suggested. Terada et al. demonstrated that influenza virus adsorbed onto the surface of human platelets in vitro, and caused platelet clumping and morphologic changes consistent with platelet damage.16 When influenza virus suspensions were infused into rabbits, a decrease in circulating platelet number occurred within 1 hour and persisted for 48 hours.I6 Others have shown that some enveloped viruses can affect cell membrane permeability directly, resulting in enhanced calcium ion f l u x e~.~J~ Severe thrombosis and vasculitis due to feline infectious peritonitis virus (FIPV) infection has been associated with immune-complex deposition in vascular lesions, thrombocytopenia, and disseminated intravascular coag~lation.~J*-~~ Evidence that an additional component to the FIPV-induced thrombocytopenia was involved was suspected because seronegative cats in a previous study4 developed reduced platelet counts as early as 4 days after inoculation of virus, i.e., at a time when an immune-complex mediated thrombocytopenia was unlikely. We hypothesized therefore that FIPV may have acted directly on platelets, the vascular endothelium, and/or on mononuclear cells, resulting in a procoagulant state. Investigating effects ofthe virus on individual cell populations in vitro seemed necessary in order to understand mechanisms of FIPV-induced coagulopathy in vivo.
The purpose of this study was to evaluate the effect of FIPV on platelet function in vitro and the effect of FIPV on platelet aggregation and *4C-~er~tonin release and potentiation of platelet responses to threshold concentrations of agonists.
Materials and Methods
Ten healthy 14-to 16-week-old, specific-pathogen-free cats were purchased from a commercial breeder (Liberty Laboratories, Liberty Comers, NJ). These cats were seronegative for feline coronavirus neutralizing antibodies and were test- Collagen-induced platelet aggregation (1.5 pg, 0.75 pg, 0.35 pg). C) Arachidonic acid-induced platelet aggregation (0.4 mM, 0.3 mM, 0.2 mM, 0.1 mM). Platelets were not radiolabeled with 14C-~er~tonin. D) Arachidonic acid-induced platelet aggregation (1.0 mM, 0.5 mM, 0.25 mM). Fig.1C and D depict the variability of feline platelet responses to arachidonic acid. Note that the feline platelet aggregation response to arachidonic acid, compared to other platelet agonists, is generally an all or none phenomenon.
negative for feline leukemia virus (ELSA). All experimental protocols were approved by an independent campus-wide animal welfare committee prior to the studies.
The DF2 strain of feline infectious peritonitis virus (FIPV, American Type Culture Collection, ATCC No. VR-2004, Rockville, MD) was used to stimulate platelets in vitro. The FIPV was propagated five times in feline embryo cells. Supernatants of infected cell cultures that had been frozenthawed three times were clarified by centrifugation at 10,000 x g. Virus was then concentrated by precipitation in polyethylene glycol (PEG-6000) followed by centrifugation at 10,000 x g for 1 hour at 4 C. Viral pellets were resuspended in TEN buffer (0.05 M Tris-maleate, 0.001 M ethylenediamine tetraacetate, 0.15 M NaCl), were dialyzed against 0.15 M NaCl for 12 hours at 4 C, and then were re-pelleted by ultracentrifugation at 210,000 x g for 1 hour at 4 C. The pellets were resuspended in TEN buffer and were then frozen and stored at -80 C until use. The titer of the purified FIPV, determined by a microtitration infectivity assay,ls was approximately 1 06.5 tissue culture infective doses (TCID,,)/O.O5 ml.
Prior to blood collection, cats were lightly anesthetized with ketamine hydrochloride (Ketaset, Bristol Laboratories, Syracuse, NY). Blood was collected via jugular venipuncture into syringes containing 3.8% trisodium citrate at a citrate to blood ratio of 1 : 9. Syringes were capped with parafilm and gently rocked at room temperature prior to isolation of platelet-rich plasma. For platelet isolation, whole blood was transferred to polycarbonate tubes and centrifuged in a swinging bucket rotor at 425-540 x g for three consecutive, 2-minute spins. Platelet-rich plasma supernatants were removed at the end of each spin, pooled, and placed into polystyrene tubes. Platelet counts were performed on plateletrich plasma with an automated platelet counter (Baker series 810, Baker Instruments Corp., Allentown, PA) and platelet counts adjusted to 250,OOO/pl with platelet-poor plasma. Platelets were radiolabeled by adding 14 pl of 0.008 pCi 14C-serotoninlpl 70% ethanol to 7 ml of platelet-rich plasma.
(Percent uptake of 14C-~er~tonin ranged from 88 to 94, mean = 92 & 2.) Imipramine (3 pM) was added to the platelets at the end of 30 minutes to prevent uptake of serotonin during release experiments. Radiolabeled platelets were evaluated in a platelet aggregometer (Chrono-log model 450, Chronolog Corp., Havertown, PA) as previously de~cribed.~J Platelet-rich plasma (0.45 ml) was stirred for 1 minute at 37 C. TEN buffer (0.05 ml) containing 106.5, lo5.,, 104.5, or 103.5 TCID,, of purified FIPV or TEN buffer alone was added to the platelet-rich plasma (viral particle to platelet ratios = 1 : 32, 1 : 320, 1 : 3,200, and 1 : 32,000, respectively). The sample was stirred for an additional 4 minutes. Viral concentrations that did not directly induce platelet aggregation or release (105.5, 104.5, and lo3., TCID5,J0.05 ml) were used to study potentiating effects of the virus on agonist-induced platelet activation. For the potentiation studies, platelet-rich plasma (0.45 ml) was allowed to stir for 1 minute at 37 C. TEN buffer or FIPV 104.5, or lo3., TCID,,JO.O5 ml) was added to the platelet-rich plasma and the sample allowed to stir for an additional minute. Threshold concentrations of agonists or 0.15 M NaCl(O.10 ml) were added and the sample allowed to stir for 3 minutes. Polystyrene microspheres (0.15 pm, Polysciences, Inc., Warrington, PA) at concentrations of 1 05.,, 1 04.5, and 1 03., were used as particulate controls. Platelet reactions were stopped by the addition of 0.125 ml of 633 mM formaldehyde in 54 mM ethylenediamine tetraacetic acid, tetrasodium salt dihydrate-0.15 M NaCl and immersion of the sample in an ice bath. Samples were immediately spun for 1 minute at 16,000 x g in an Eppendorf centrifuge (Model 5414, Hamburg, W. Germany) and 0.05 ml of supernatant removed for scintillation counting. Threshold concentrations of agonists were selected as the highest concentration of a particular compound that induced minimal platelet aggregation or release in samples from the majority of cats studied. (Dose response data for ADP, collagen, and arachidonic acid are presented in Fig Arachidonic acid (Nu Chek Prep, Elysian, MN) was dissolved in 0.05 M Tris-0.15 M NaCl, pH 7.4 (10 mM stock) and aliquots purged with 0,-free nitrogen prior to freezing at -80 C . Other agonists were maintained and diluted as described elsewhere., Agonists were thawed and kept on ice until immediately prior to use. Three samples were selected at random and the platelet potentiation experiments using FIPV at a concentration of 105.5 TCID5,,/0.05 ml repeated with unlabeled platelet-rich plasma. At the end of the reaction in the aggregometer, samples were immediately spun without the addition of formaldehyde. Supernatant plasma was removed, and 0.5 ml of 3% glutaraldehyde was added to the platelet pellet for evaluation by transmission electron micro~copy.~
Results

Virus dose response studies
At a concentration of 1 06.5 tissue culture infective doses (TCID),,JO.O5 ml, feline infectious peritonitis virus (FIPV) induced direct, irreversible, platelet aggregation and release in most samples (Fig. 2) . When the concentration of FIPV was reduced to 1 05.5 TCID,,/ 0.05 ml, direct platelet activation was either absent or minimal. Potentiation of platelet responses to threshold concentrations of agonists, however, was demonstrated ( Fig. 3 and Table 1 ). Decreasing the concentration of FIPV to lo4., or 103.5 TCID5,J0.05 ml resulted in a decrease or loss of the potentiating effect (Fig. 4) . Polystyrene microspheres (0.15 pm in diameter) at concentrations of 105.5, lo4.,, or 103,5/0.05 ml were substituted for viral particles in particulate control experiments (Fig. 5) . The microspheres neither induced nor potentiated feline platelet aggregation or release. The following sections detail the results in which potentiation of platelet responses were observed at FIPV concentrations of TCID,,/O.OS ml.
ADP-induced platelet aggregation and release
ADP (1 pM), in the presence of suspension buffer without viral particles, induced less than a 10% change in light transmittance in eight of ten samples (Fig. 3A) . Two samples exhibited changes in light transmittance of 43 and 44%. This data supported earlier observations indicating that in the majority of cats, the threshold concentration of ADP inducing irreversible platelet aggregation was approximately 2 pM (see Fig. 1 for a typical dose response curve to ADP in cats). Platelet 14C-serotonin release was less than 5% for the eight weakly reacting samples and 5 and 8% for the latter two samples. In the presence of viral particles, the change in light transmittance observed at the end of 5 minutes was increased by greater than 100% in seven samples. The range in light transmittance observed for these samples was 4 to 63% (mean = 29 * 23%). Only one of the two samples with high baseline reactivity to ADP showed an increase in light transmittance in the presence of viral particles; the increase, however, was not greater than 100%. An increase in platelet I4C-serotonin release of greater than 100% was only observed in four samples, the range for these samples being 7 to 25% (mean = 14 f 8%).
Collagen-induced platelet aggregation and release
Collagen (0.3 pg) induced a 10% or less change in light transmittance in eight of ten samples in the absence of viral particles (Fig. 3B) . In two samples the change in light transmittance was 15 and 23%. When FIPV was present, all ten samples demonstrated an increase in light transmittance of greater than 100% in response to the same concentration of collagen. The range in light transmittance for these samples was 8 to 62% (mean = 34 & 16%). Platelet 14C-~er~tonin release was 10% or less in eight of ten samples in the absence of viral particles; two samples exhibited release responses of 1 1 and 15%. In the presence of FIPV, eight samples responded to 0.3 pg collagen with a greater than 100% increase in platelet 14C-~er~tonin release over that observed with buffer alone. The range for these samples was 6 to 33% (mean = 22 * 9%). Feline infectious peritonitis virus potentiated the epinephrine-induced aggregation response in five samples, the responses were characterized by microaggregate formation. Platelet 14C-~er~tonin release was not potentiated in any samples. E) Feline infectious peritonitis virus alone at the above concentration induced microaggregate formation in three samples. Feline infectious peritonitis virus at this concentration did not induce significant 14C-~er~tonin release in any samples.
Arachidonic acid-induced platelet aggregation and release
Baseline arachidonic acid (0.2 mM) responses were variable and ranged from 10 to 68% (mean = 46 f 2 1 %). For an example of the variability encountered in feline platelet responses to arachidonic acid, see Fig.  1 . Unlike other agonists, arachidonic acid induces an all or none platelet aggregation response preceded by a variable lag phase somewhat proportional to the concentration of agonist used. This phenomenon made prediction of a threshold response difficult. Increases in light transmittance of greater than 100% in the presence of FIPV were only observed in three samples (Fig.  3C) . These samples had a light transmittance range of 10 to 22% in the absence of virus and a range of 7 1 to 77% in the presence of virus. In the absence of virus, percent 14C-~er~tonin release ranged from 5 to 48 (mean = 24 f 13). In the presence of virus, only two samples demonstrated an increase in platelet 14C-~er~tonin release of greater than 100%. At baseline, the release response for these two samples was 5 and 12%. In the presence of virus, the release response was 29 and 49%.
Epinephrine-induced platelet aggregation and release
Epinephrine (20 pM) did not induce detectable aggregation in any of the samples in the absence of virus (Fig. 3D) . In the presence of virus, five samples showed microaggregate formation in response to epinephrine. The change in light transmittance for these samples ranged from 4 to 7%. Visual inspection of the cuvette at the end of the reaction confirmed the presence of fine microaggregates. Significant platelet 14C-serotonin release did not occur in any of the samples (consistently less that 5%) either in the absence or presence of virus. 
FIPV-induced platelet aggregation and release
At a concentration of 105.5 TCID5,/0.05 ml, virus alone either failed to induce platelet aggregation (seven samples) or induced microaggregate formation (three samples); these aggregates appeared similar to those described previously, with epinephrine in the presence of virus (Fig. 3E) . The light transmittance for the latter samples ranged from 5 to 7%. Platelet I4C-serotonin release was less than 5% in all samples. 
Electron microscopic results
Within 5 minutes of the addition of virus to stirred platelet suspensions, coronavirus particles were demonstrated in the extracellular space between platelets, were closely associated and attached to platelet surface membranes, and were internalized within the open canalicular system (Fig. 6a-e) . Virus-platelet membrane interactions were characterized morphologically by the formation of bridges of fine filamentous material extending perpendicularly between the virus membrane and through the subjacent platelet membrane (Fig. 6b) . Virus-platelet interactions were observed in platelet samples exhibiting microaggregate formation in response either to virus alone or to virus-agonist combinations; samples showing strong aggregation responses could not be evaluated due to loss of cellular detail.
Discussion
At a concentration of 1 05.5 tissue culture infective doses (TCID),,/O.O5 ml (virus to platelet ratio = 1 : 320), feline infectious peritonitis virus (FIPV) potentiated ADP-and collagen-induced platelet responses in vitro (i.e., responses were increased by > 100% of baseline values). Epinephrine-induced platelet aggregation was enhanced in 50% of the cats and was characterized by microaggregate formation. Enhanced arachidonic acid-induced platelet responses were demonstrated in only three cats; however, this may have been due to the relatively high concentration of the agonist used. In the absence of virus, arachidonic acid at a final concentration of 0.2 mM induced vigorous platelet responses in seven of ten cats (light transmittance ranged from 42 to 68%), making detection of an enhanced response in the presence of virus difficult. In contrast, the three cats in which virus potentiation of arachidonic acid-induced platelet aggregation was demonstrated had initial platelet aggregation responses Microaggregate formation was induced directly by FIPV in three samples; the macroscopic appearance of these samples was similar to that observed with viruspotentiated epinephrine responses. Direct strong platelet activation occurred only when the virus concentration was increased tenfold.
A series of events, including binding of viral particles to the outer platelet membrane and uptake of viral particles within the open canalicular system, was demonstrated by electron microscopy in selected samples that were minimally activated in vitro. Complete internalization of viral particles in the open canalicular system occurred within 5 minutes of addition of virus to stirred platelet suspensions.
Feline infectious peritonitis is a lethal, coronavirusinduced immunopathologic disease of cats that is charof only 10 to 22%. acterized by severe, diffise thrombosis and vasculitis. Vascular changes and disseminated intravascular coagulation can occur in the subacute and chronic stages of disease and are associated with immune-complex deposition within the vascular e n d o t h e l i~m . '~J~J~J~ The occurrence of disseminated intravascular coagulation and thrombocytopenia as early as 4 days post-inoculation of virus in some specific-pathogen-free however, suggests that nonimmunological mechanisms may also contribute initially to the disease. These mechanisms may involve direct viral effects on vascular endothelium or mononuclear inflammatory cells and/or platelets, resulting in a procoagulant state. As a result of ultrastructural studies of bluetongue virus, Howerth and Tyler8 suggested a direct effect by virus on vascular endothelium. In a study by Axthelm and Krakowka,' canine distemper virus-induced thrombocytopenia occurred as early as 5 days post-inoculation of gnotobiotic dogs, i.e., at least 2 days before platelet-associated virus could be detected immunocytochemically in peripheral blood. This still does not eliminate the possibility of a direct effect of virus on platelets early in infection. If platelets that have interacted directly with viral particles indeed display enhanced reactivity (as demonstrated with FIPV in our study), rapid in vivo clearance of affected platelets would be likely. The elution of viral particles from the surface of platelets after induction of membrane permeability changes might also account for shortened platelet survival in the absence of detectable viral antigen.I4 Other examples of direct viral effects in vitro on cell membrane permeability (reviewed by Pa~ternak'~) include viral-induced loss of the capacity by neurons to fire an action potential; the induction of hormone release from anterior pituitary cells; and the cessation of beating by cultured heart cells.
In this study, the contribution of the vascular endothelium or mononuclear inflammatory cells to early viral-induction of a procoagulant state was not evaluated. The distinct potentiating effect of FIPV on platelet activation observed in vitro may explain the acute thrombocytopenia observed in vivo. Paramyxoviruses can induce membrane permeability changes in cells, resulting in enhanced calcium m~v e m e n t .~ Calcium is recognized as a second messenger important in normal response-coupled platelet a c t i~a t i o n .~,~~ The assembly of platelet cytoskeleton microfilaments is preceded by increases in the concentration of ionized calcium.' Possibly, small calcium fluxes induced by FIPV were responsible for the potentiating effects we observed. l7 In our study, electron-dense, microfilamentous connections were observed between virus and platelet membranes, suggesting that FIPV-induced membrane perturbation and intra-or extracellular calcium fluxes (or both) possibly were involved. Because exposing platelets to inert microspheres of similar size was not as-sociated with altered platelet responses, this phenomenon appeared to be viral-induced.
The phenomenon of FIPV-enhanced platelet activation in vitro was supported in vivo by the demonstration of potentiated platelet responses in cats 4 days after intraperitoneal inoculation of FIPV.5 Although direct virus-platelet interaction was not demonstrated in that study, the results of our in vitro study suggested that similar virus-platelet interactions might occur in vivo. If the mechanism for FIPV-induced platelet potentiation or activation is via induction of ion fluxes across the platelet membrane, then there is the possiblity of a similar effect of virus on other cell types. Potentially, viral-induced ion fluxes across endothelial cells could result in changes in the endothelial cell membrane such that platelets interact more readily with the endothelial cell surface. Viral-induced ion fluxes across mononuclear cell membranes also may result in the expression of receptors that enhance the hemostatic mechanism. If either of these events occur in vivo, thrombocytopenia might occur. The early interaction of FIPV with other cells, including endothelial cells and mononuclear inflammatory cells, and the effect of these interactions on the induction of an acute procoagulant state still need to be addressed.
